You are here

Impact of Inhaled Corticosteroid–Induced Oropharyngeal Side Effects on Treatment Patterns and Costs in Asthmatic Patients: Results from a Delphi Panel

Michael Kaliner, MD; Alpesh Amin, MD, MBA, Ronald Gehling, MD, PharmD, Concetta Crivera, PharmD, Evelyn Chiao, PharmD, Tejal Vishalpura, PharmD, and Thomas Bramley, PhD
PDF version: 
Inhaled corticosteroid (ICS) therapy can be associated not only with rare systemic adverse events (ADEs) but also, more commonly, with oropharyngeal ADEs. The authors investigate the economic burden of ICS treatment.